Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708661 | 0.91 | LMNA (0.47) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL7903528 | 0.85 | HDAC1 (0.62) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL6862763 | 0.83 | HDAC1 (0.49) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL6859239 | 0.79 | FFAR4 (0.46) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL22660216 | 0.78 | HDAC1 (0.43) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL7900388 | 0.78 | HDAC1 (0.54) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL15779663 | 0.78 | HDAC1 (0.71) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL15150399 | 0.78 | LMNA (0.49) | LMNACYP4F2CYP4A11ALOX5SMN1; SMN2 | |
| SCHEMBL15779667 | 0.77 | HDAC1 (0.58) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL15779672 | 0.77 | HDAC1 (0.53) | HDAC1HDAC6HDAC2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | disclosed |
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | ITGB1, ITGA1, ITGB3 | HDAC1 98/4885HDAC6 306/4885HDAC2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.